Hepatoma cell line HepG2.2.15 demonstrates distinct biological features compared with parental HepG2.

World Journal of Gastroenterology : WJG
Ran ZhaoXiao-Ming Jin

Abstract

To investigate the biological features of hepatitis B virus (HBV)-transfected HepG2.2.15 cells. The cell ultrastructure, cell cycle and apoptosis, and the abilities of proliferation and invasion of HBV-transfected HepG2.2.15 and the parent HepG2 cells were examined by electron microscopy, flow cytometry, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and trans-well assay. Oncogenicity of the two cell lines was compared via subcutaneous injection and orthotopic injection or implantation in nude mice, and the pathological analysis of tumor formation was performed. Two cytoskeletal proteins were detected by Western blotting. Compared with HepG2 cells, HepG2.2.15 cells showed organelle degeneration and filopodia disappearance under electron microscope. HepG2.2.15 cells proliferated and migrated slowly in vitro, and hardly formed tumor and lung metastasis in nude mice. Flow cytometry showed that the majority of HepG2.2.15 cells were arrested in G1 phase, and apoptosis was minor in both cell lines. Furthermore, the levels of cytoskeletal proteins F-actin and Ezrin were decreased in HepG2.2.15 cells. HepG2.2.15 cells demonstrated a lower proliferation and invasion ability than the HepG2 cells due to HBV transfection.

References

Feb 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M A SellsG Acs
May 25, 2002·Seminars in Cancer Biology·Isaiah J Fidler
Aug 3, 2002·Nature Reviews. Molecular Cell Biology·Anthony BretscherRichard G Fehon
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
Sep 16, 2005·The New England Journal of Medicine·Jiang HePaul K Whelton
Oct 19, 2005·European Urology·Alexander ValdmanLars Egevad
Dec 15, 2005·The Journal of Pathology·David Wai Chan, Irene Oi-lin Ng
Aug 19, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Yutaka FurutaniYoshihiro Yoshihara

❮ Previous
Next ❯

Citations

May 10, 2013·Archives of Pharmacal Research·Do Kyung LeeNam Joo Ha
Dec 18, 2012·The Journal of Clinical Investigation·Heping YangShelly C Lu
Aug 14, 2012·International Journal of Nanomedicine·Haitham AmalHossam Haick
Jan 15, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Tianzhen WangFengmin Zhang
Mar 23, 2017·PloS One·Teppei YoshiokaTetsuo Takehara
Aug 12, 2018·Molecular & Cellular Proteomics : MCP·Jiradej MakjaroenTrairak Pisitkun
May 30, 2019·American Journal of Physiology. Gastrointestinal and Liver Physiology·Murali GanesanNatalia A Osna
Aug 7, 2020·American Journal of Physiology. Gastrointestinal and Liver Physiology·Murali GanesanNatalia A Osna
Jan 13, 2017·Lipids in Health and Disease·Chengliang ZhuXinghui Liu
Nov 1, 2018·Molecular & Cellular Proteomics : MCP·Jiradej MakjaroenTrairak Pisitkun
Mar 25, 2021·Infectious Agents and Cancer·Shouhua ZhangJinlong Yan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.